Clinical evidence
Validated against laboratory urine culture across 846 patient samples.
Overall performance
Clinical validation across the six-pathogen panel.
The Lodestar UTI testing system has been clinically validated from 846 patient samples evaluated against laboratory urine culture at Public Health Wales, Cardiff and Norfolk & Norwich Microbiology Services.
| Assay | Sensitivity % | Specificity % | Accuracy % |
|---|---|---|---|
| Escherichia coli | 89 | 93 | 92 |
| Enterococcus species | 74 | 92 | 91 |
| Staphylococcus saprophyticus | 89 | 98 | 97 |
| Proteus mirabilis | 91 | 96 | 96 |
| Pseudomonas aeruginosa | 88 | 94 | 94 |
| Klebsiella pneumoniae | 100 | 94 | 95 |
Clinical Performance Evaluation, n=846 | Diggle et al, JAC-AMR, 2024 and Drazich-Taylor et al, JAC-AMR, 2025
Additional evaluations undertaken at Royal Berkshire (n=80) and The Forbury Clinic (n=103) and published as abstracts at EAU Congress 2026 and AUA Congress 2026.
Pre-operative urine screening
Rapid rule-out before urological procedures.
92%NPV
n=189, pre-operative urology screening
Asymptomatic bacteriuria before urological surgery currently relies on either empirical treatment or a culture wait that delays the procedure. The Lodestar UTI testing system delivers a 35-minute pathogen ID result at the point of pre-op assessment — informing targeted antibiotic selection where bacteriuria is present, and reducing the number of cancelled procedures.
Llusern Scientific. Clinical Performance of the Lodestar UTI Testing System for Preoperative Urology Screening, January 2026.
Important Information
Lodestar DX is UKCA-marked. For in vitro diagnostic use only. Use in conjunction with the full clinical profile of the patient. A positive result does not guarantee that an infection is present; a negative result does not rule out the possibility of a UTI.
Change the way you manage UTIs.
Evaluate the Lodestar UTI testing system in your clinical setting. The Syner-Med team supports evaluation requests across the UK.